![BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine](https://www.science.org/cms/asset/3facfaaf-3a34-40b3-abc8-407badc84579/stm.2020.12.issue-531.largecover.jpg)
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine
![BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC](https://europepmc.org/articles/PMC8662740/bin/nihms-1731291-f0005.jpg)
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. - Abstract - Europe PMC
![BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers | Science Translational Medicine](https://www.science.org/cms/asset/aff01e29-3536-466a-9bbc-a839e7e344f4/aax2625-f1.gif)